SIRAKOSS

Aberdeen, United Kingdom Founded: 2010 • Age: 16 yrs Acquired By OssDsign
Synthetic bone graft substitutes for trauma and spine indications.
Request Access

About SIRAKOSS

SIRAKOSS is a company based in Aberdeen (United Kingdom) founded in 2010 was acquired by OssDsign in November 2020.. SIRAKOSS has raised $4.8 million across 3 funding rounds from investors including Gov.uk, OssDsign and Scottish Enterprise. SIRAKOSS offers products and services including OssDsign Catalyst. SIRAKOSS operates in a competitive market with competitors including Theradaptive, MiMedx Group, Ossio, RevBio and Aziyo Biologics, among others.

  • Headquarter Aberdeen, United Kingdom
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Ossdsign Ab
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $4.8 M (USD)

    in 3 rounds

  • Latest Funding Round
    $226.83 K (USD), Grant

    Jul 25, 2016

  • Investors
    Gov.uk

    & 4 more

  • Employee Count
    Employee Count
  • Acquired by
    OssDsign

    (Nov 03, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SIRAKOSS

SIRAKOSS offers a comprehensive portfolio of products and services, including OssDsign Catalyst. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Nanosynthetic graft for rapid bone formation in surgical fusions.

Funding Insights of SIRAKOSS

SIRAKOSS has successfully raised a total of $4.8M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $226.83 thousand completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $226,825
  • First Round

    (02 Dec 2014)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2016 Amount Grant - SIRAKOSS Valuation

investors

Dec, 2014 Amount Grant - SIRAKOSS Valuation

investors

Dec, 2014 Amount Series A - SIRAKOSS Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SIRAKOSS

SIRAKOSS has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, OssDsign and Scottish Enterprise. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Online government services and information are provided to users.
Founded Year Domain Location
Business development and leadership training programs are offered to companies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SIRAKOSS

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SIRAKOSS

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sirakoss Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SIRAKOSS

SIRAKOSS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Theradaptive, MiMedx Group, Ossio, RevBio and Aziyo Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutic delivery platform is developed for orthopedic clinical indications.
domain founded_year HQ Location
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
domain founded_year HQ Location
Orthopedic fixation is enabled by bone regeneration biocomposite technology.
domain founded_year HQ Location
Synthetic adhesives for bone and dental repair are developed.
domain founded_year HQ Location
Regenerative medicine products are developed for orthopedic and cardiovascular applications.
domain founded_year HQ Location
Developer of stem cells to regrow damaged bones
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sirakoss

Frequently Asked Questions about SIRAKOSS

When was SIRAKOSS founded?

SIRAKOSS was founded in 2010 and raised its 1st funding round 4 years after it was founded.

Where is SIRAKOSS located?

SIRAKOSS is headquartered in Aberdeen, United Kingdom. It is registered at Aberdeen, Scotland, United Kingdom.

Is SIRAKOSS a funded company?

SIRAKOSS is a funded company, having raised a total of $4.8M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.47M, raised on Dec 02, 2014.

What does SIRAKOSS do?

SIRAKOSS was founded in 2010 as a spin-out from the University of Aberdeen and is based in Aberdeen City, Scotland. The company operates in the medical device sector, focusing on synthetic bone graft substitutes for treating bone defects and fusions in trauma and spinal applications. Its portfolio features MaxSi graft granules in standard sizes and MaxSi graft putty, which can be reshaped, with performance validated in pre-clinical models.

Who are the top competitors of SIRAKOSS?

SIRAKOSS's top competitors include EpiBone, Theradaptive and MiMedx Group.

What products or services does SIRAKOSS offer?

SIRAKOSS offers OssDsign Catalyst.

Who are SIRAKOSS's investors?

SIRAKOSS has 5 investors. Key investors include Gov.uk, OssDsign, Scottish Enterprise, Epidarex Capital, and Armourers' Hall.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available